New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 24, 2012
10:25 EDTVPHM, STR, CTB, TWX, PVH, BODY, RHI, RBCN, LAMR, AGNOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Allergan (AGN) upgraded to Outperform from Underperform at CLSA... Body Central (BODY) upgraded to Outperform from Perform at Oppenheimer... Cooper Tire (CTB) upgraded to Buy from Hold at Deutsche Bank... Lamar Advertising (LAMR) upgraded to Outperform from Market Perform at Wells Fargo... PVH Corp. (PVH) upgraded to Overweight from Neutral at Piper Jaffray... Questar (STR) upgraded to Buy from Neutral at UBS... Rubicon (RBCN) upgraded to Neutral from Sell at Goldman... Time Warner (TWX) upgraded to Overweight from Equal Weight at Morgan Stanley... ViroPharma (VPHM) upgraded to Outperform from Market Perform at Wells Fargo... Robert Half (RHI) upgraded to Buy from Neutral at BofA/Merrill.
News For AGN;BODY;CTB;LAMR;PVH;STR;RBCN;TWX;VPHM;RHI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
February 19, 2015
08:15 EDTTWXWarner Bros. exec says not in talks with Apple on streaming, Re/code reports
Subscribe for More Information
07:40 EDTAGNActavis price target raised to $352 from $300 at Canaccord
Subscribe for More Information
07:25 EDTTWXCable nets speed up shows to add more ads, WSJ says
Subscribe for More Information
February 18, 2015
18:54 EDTSTRQuestar announces executive promotions
Questar announced executive promotions in two of its subsidiaries and its corporate group. Effective immediately, Thomas C. Jepperson will assume new duties as COO of Questar. Jepperson has served in many positions in his 26 years with Questar, including general counsel and corporate secretary, and has held leadership positions in the areas of compliance, environmental health and safety, and human relations. Effective June 1, Brady B. Rasmussen will assume the duties of executive VP and COO of Wexpro, Questar’s natural gas development and production arm. Rasmussen will replace James R. Livsey, who has announced his intention to retire. Rasmussen has been with the company for 20 years in various positions. Rasmussen will report to Jepperson. Effective March 1, Colleen Larkin Bell, currently vice president and assistant general counsel, has been promoted to vice president and general counsel of Questar. Bell will report directly to Questar chairman, president and CEO Ron Jibson. Questar promoted Vaughn Shosted to vice president, operations, Questar Gas Company.
17:28 EDTSTRQuestar sees FY15 EPS $1.20-$1.30, consensus $1.33
Subscribe for More Information
17:27 EDTSTRQuestar reports Q4 EPS 35c, consensus 38c
Subscribe for More Information
16:46 EDTAGNOn The Fly: Closing Wrap
Subscribe for More Information
14:03 EDTSTRQuestar corrects record date for increased 21c dividend
As previously reported, Questar's board approved an 11% increase in the quarterly common stock cash dividend to 21c. The dividend is a 2c increase from the previous quarter and results in a new annualized dividend rate of 84c per share. Questar also announced earlier that it raised its target dividend payout ratio to 65% from 60%. The company issued a correction to note that the dividend is payable March 16, to shareholders of record on March 2.
12:31 EDTAGNOn The Fly: Midday Wrap
Subscribe for More Information
10:42 EDTPVHApparel makers beyond Perry Ellis seen hurt by port slowdown
Subscribe for More Information
09:48 EDTAGNActavis Q4 'exceptional,' taking Allergan name 'wise,' says BMO Capital
BMO Capital says Actavis (ACT) is "firing on all cylinders" after reporting "exceptional" Q4 earnings on the strength of the company's North American Generics and International segment. BMO views the decision to adopt the Allergan (AGN) name as "wise" given the Botox maker's strong reputation. The firm keeps an Outperform rating on Actavis.
07:50 EDTAGNActavis CEO says company gave appropriate guidance to analysts
Actavis (ACT) CEO Saunders said he believes that the company did provide appropriate guidance to analysts ahead of its earnings beat. Saunders sees the Allergan (AGN) deal closing by the end of this quarter or early next quarter. Saunders says tying R&D to a percentage of revenue "makes no sense to me," noting that Actavis will spend about $1.7B on R&D next year. Saunders says will do acquisition if opportunity arises, but not planning for M&A right now. Actavis CEO Brent Saunders is speaking on CNBC.
07:01 EDTAGNActavis announces intention to adopt 'Allergan' corporate name
Subscribe for More Information
06:34 EDTAGNActavis sees Allergan transaction completed in late Q1 or early Q2
February 17, 2015
18:43 EDTPVHApparel stocks lower after Perry Ellis warns of West Coast port disruption
Subscribe for More Information
18:06 EDTAGNPaulson & Co gives quarterly update on stakes
Subscribe for More Information
17:18 EDTAGNPershing Square gives quarterly update on stakes
NEW STAKES: Restaurant Brands International (QSR). INCREASED STAKES: Zoetis (ZTS), and Platform Specialty Products (PAH). DECREASED STAKES: Allergan (AGN). LIQUIDATED STAKES: None.
17:02 EDTAGNSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
13:52 EDTAGNEarnings Preview: Actavis near 52-week high ahead of Q4 earnings report
Subscribe for More Information
13:18 EDTTWXOmega Advisors gives quarterly update on stakes
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use